|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
SELECT PUBLICATIONS Dang C et al. Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/ neu overexpressed/Amplified breast cancer (BCA). San Antonio Breast Cancer Symposium 2005;Poster 2041. Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005a;Abstract 16. Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005b;97(17):1262-71. Abstract Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract HERA Study Team. Trastuzumab (H: Herceptin) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 11. Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. San Antonio Breast Cancer Symposium 2005;Abstract 17. Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract Joensuu H et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer Trial. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 2. Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Presentation. San Antonio Breast Cancer Symposium 2005.Abstract 46. Mamounas EP. Can we approach zero relapse in breast cancer? Oncologist 2005;10 (Suppl 2):9-17. Abstract Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3. Perez EA et al. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? San Antonio Breast Cancer Symposium 2005;Poster 2038. Piccart-Gebhart MJ. Treatment guidelines for systemic adjuvant therapy of breast cancer: strengths and weaknesses. San Antonio Breast Cancer Symposium 2005a;Abstract P1. Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005b;353(16):1659- 72. Abstract Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Poster 1045. Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (AC Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract Toi M et al. Trastuzumab: Updates and future issues. Cancer Chemother Pharmacol 2005;56(Suppl 1):94-9. Abstract
|
|
 |
Terms and Conditions of Use and General Disclaimer Copyright © 2006 Research To Practice. All Rights Reserved |
 |
T) with doxorubicin and cyclophosphamide
followed by docetaxel and trastuzumab (AC
